Cathepsin L targeting in cancer treatment

Pharmacology and Therapeutics

Volumn 155, Issue , 2015, Pages 105-116

  Sudhan, Dhivya R ^a   Siemann, Dietmar W ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone resorption; Cancer; Cathepsin L; Metastasis; Protease targeting

Indexed keywords

CATHEPSIN L; CYSTEINE PROTEINASE INHIBITOR;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; HUMAN; LIFE EXPECTANCY; METASTASIS; METASTASIS INHIBITION; MORBIDITY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS;

ANIMALS; CATHEPSIN L; CYSTEINE PROTEINASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84945460903     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.08.007     Document Type: Review

References (204)

1. A. Adenis, G. Huet, F. Zerimech, B. Hecquet, M. Balduyck, and J.P. Peyrat Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters Cancer Lett 96 1995 267 275
2. A.M. Anestakis Doxakis, Petanidis Savvas, and Iakovidou-Kritsi Zafiroula Assessment of the roles of cathepsins B, H and L in the progression of colorectal cancer J Cancer Ther 4 2013 1 7
3. K. Asanuma, I. Shirato, K. Ishidoh, E. Kominami, and Y. Tomino Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes Kidney Int 62 2002 822 831
4. A. Barbarin, and R. Frade Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells Biochem J 437 2011 97 107
5. W.H. Baricos, Y. Zhou, R.W. Mason, and A.J. Barrett Human kidney cathepsins B and L. Characterization and potential role in degradation of glomerular basement membrane Biochem J 252 1988 301 304
6. A.J. Barrett, and H. Kirschke Cathepsin B, Cathepsin H, and cathepsin L Methods Enzymol 80 Pt C 1981 535 561
7. K.M. Bell-McGuinn, A.L. Garfall, M. Bogyo, D. Hanahan, and J.A. Joyce Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer Cancer Res 67 2007 7378 7385
8. G. Blum, G. von Degenfeld, M.J. Merchant, H.M. Blau, and M. Bogyo Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes Nat Chem Biol 3 2007 668 677
9. T. Bogenrieder, and M. Herlyn Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma Crit Rev Oncol Hematol 44 2002 1 15
10. P. Bouwman, A. Aly, J.M. Escandell, M. Pieterse, J. Bartkova, H. van der Gulden, and et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat Struct Mol Biol 17 2010 688 695
11. T.E. Cawston, and D.A. Young Proteinases involved in matrix turnover during cartilage and bone breakdown Cell Tissue Res 339 2010 221 235
12. A.F. Chambers, R. Colella, D.T. Denhardt, and S.M. Wilson Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells Mol Carcinog 5 1992 238 245
13. S.S. Chauhan, L.J. Goldstein, and M.M. Gottesman Expression of cathepsin L in human tumors Cancer Res 51 1991 1478 1481
14. G.E. Chavarria, M.R. Horsman, W.M. Arispe, G.D. Kumar, S.E. Chen, T.E. Strecker, and et al. Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L Eur J Med Chem 58 2012 568 572
15. Q. Chen, L. Chen, R. Zhao, X.D. Yang, K. Imran, and C.G. Xing Microarray analyses reveal liver metastasis-related genes in metastatic colorectal cancer cell model J Cancer Res Clin Oncol 139 2013 1169 1178
16. Q. Chen, J. Fei, L. Wu, Z. Jiang, Y. Wu, Y. Zheng, and et al. Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients Oncol Lett 2 2011 693 699
17. P. Clezardin Therapeutic targets for bone metastases in breast cancer Breast Cancer Res 13 2011 207
18. R. Colella, T. Jackson, and E. Goodwyn Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L + B activity Biotech Histochem 79 2004 121 127
19. L.M. Coussens, B. Fingleton, and L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 295 2002 2387 2392
20. S.W. Cox, B.M. Eley, M. Kiili, A. Asikainen, T. Tervahartiala, and T. Sorsa Collagen degradation by interleukin-1beta-stimulated gingival fibroblasts is accompanied by release and activation of multiple matrix metalloproteinases and cysteine proteinases Oral Dis 12 2006 34 40
21. C. Cuvier, A. Jang, and R.P. Hill Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion Clin Exp Metastasis 15 1997 19 25
22. C. Damiens, E. Grimaud, A.V. Rousselle, C. Charrier, Y. Fortun, D. Heymann, and et al. Cysteine protease production by human osteosarcoma cells (MG63, SAOS2) and its modulation by soluble factors Cytokine 12 2000 539 542
23. Y.A. DeClerck, A.M. Mercurio, M.S. Stack, H.A. Chapman, M.M. Zutter, R.J. Muschel, and et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section Am J Pathol 164 2004 1131 1139
24. D.T. Denhardt, A.H. Greenberg, S.E. Egan, R.T. Hamilton, and J.A. Wright Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts Oncogene 2 1987 55 59
25. D.T. Denhardt, R.T. Hamilton, C.L. Parfett, D.R. Edwards, St Pierre, R. Waterhouse, and et al. Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins Cancer Res 46 1986 4590 4593
26. J. Dennemarker, T. Lohmuller, S. Muller, S.V. Aguilar, D.J. Tobin, C. Peters, and et al. Impaired turnover of autophagolysosomes in cathepsin L deficiency Biol Chem 391 2010 913 922
27. V. Devauchelle, S. Marion, N. Cagnard, S. Mistou, G. Falgarone, M. Breban, and et al. DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets Genes Immun 5 2004 597 608
28. A. Dohchin, J.I. Suzuki, H. Seki, M. Masutani, H. Shiroto, and Y. Kawakami Immunostained cathepsins B and L correlate with depth of invasion and different metastatic pathways in early stage gastric carcinoma Cancer 89 2000 482 487
29. P.J. Doherty, L. Hua, G. Liau, S. Gal, D.E. Graham, M. Sobel, and et al. Malignant transformation and tumor promoter treatment increase levels of a transcript for a secreted glycoprotein Mol Cell Biol 5 1985 466 473
30. J.M. Dong, E.M. Prence, and G.G. Sahagian Mechanism for selective secretion of a lysosomal protease by transformed mouse fibroblasts J Biol Chem 264 1989 7377 7383
31. B.T. Elie, V. Gocheva, T. Shree, S.A. Dalrymple, L.J. Holsinger, and J.A. Joyce Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model Biochimie 92 2010 1618 1624
32. V. Everts, W. Korper, K.A. Hoeben, I.D. Jansen, D. Bromme, K.B. Cleutjens, and et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone J Bone Miner Res 21 2006 1399 1408
33. F. Farinati, L. Herszenyi, M. Plebani, P. Carraro, M. De Paoli, R. Cardin, and et al. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis Carcinogenesis 17 1996 2581 2587
34. U. Felbor, B. Kessler, W. Mothes, H.H. Goebel, H.L. Ploegh, R.T. Bronson, and et al. Neuronal loss and brain atrophy in mice lacking cathepsins B and L Proc Natl Acad Sci U S A 99 2002 7883 7888
35. B. Fingleton Matrix metalloproteinases as valid clinical targets Curr Pharm Des 13 2007 333 346
36. J.F. Fisher, and S. Mobashery Recent advances in MMP inhibitor design Cancer Metastasis Rev 25 2006 115 136
37. J.A. Foekens, J. Kos, H.A. Peters, M. Krasovec, M.P. Look, N. Cimerman, and et al. Prognostic significance of cathepsins B and L in primary human breast cancer J Clin Oncol 16 1998 1013 1021
38. I. Fogelman, G.M. Blake, R. Blamey, M. Palmer, W. Sauerbrei, M. Schumacher, and et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) Osteoporos Int 14 2003 1001 1006
39. R. Frade, F. Rodrigues-Lima, S. Huang, K. Xie, N. Guillaume, and M. Bar-Eli Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells Cancer Res 58 1998 2733 2736
40. R. Frade, N. Rousselet, and D. Jean Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells Cancer Gene Ther 15 2008 591 604
41. K.K. Frick, P.J. Doherty, M.M. Gottesman, and C.D. Scher Regulation of the transcript for a lysosomal protein: evidence for a gene program modified by platelet-derived growth factor Mol Cell Biol 5 1985 2582 2589
42. B. Friedrich, K. Jung, M. Lein, I. Turk, B. Rudolph, G. Hampel, and et al. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue Eur J Cancer 35 1999 138 144
43. E. Frohlich, B. Schlagenhauff, M. Mohrle, E. Weber, C. Klessen, and G. Rassner Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma Cancer 91 2001 972 982
44. L. Funkelstein, T. Toneff, C. Mosier, S.R. Hwang, F. Beuschlein, U.D. Lichtenauer, and et al. Major role of cathepsin L for producing the peptide hormones ACTH, beta-endorphin, and alpha-MSH, illustrated by protease gene knockout and expression J Biol Chem 283 2008 35652 35659
45. N. Furuyama, and Y. Fujisawa Regulation of collagenolytic cysteine protease synthesis by estrogen in osteoclasts Steroids 65 2000 371 378
46. N. Furuyama, and Y. Fujisawa Regulation of collagenolytic protease secretion through c-Src in osteoclasts Biochem Biophys Res Commun 272 2000 116 124
47. S. Gal, and M.M. Gottesman The major excreted protein of transformed fibroblasts is an activable acid-protease J Biol Chem 261 1986 1760 1765
48. S. Gal, and M.M. Gottesman Isolation and sequence of a cDNA for human pro-(cathepsin L) Biochem J 253 1988 303 306
49. S. Gal, M.C. Willingham, and M.M. Gottesman Processing and lysosomal localization of a glycoprotein whose secretion is transformation stimulated J Cell Biol 100 1985 535 544
50. E. Gallardo, I. de Andres, and I. Illa Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis J Neuropathol Exp Neurol 60 2001 847 855
51. A. Gerber, A. Wille, T. Welte, S. Ansorge, and F. Buhling Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells J Interferon Cytokine Res 21 2001 11 19
52. A. Gianotti, C.A. Sommer, A.K. Carmona, and F. Henrique-Silva Inhibitory effect of the sugarcane cystatin CaneCPI-4 on cathepsins B and L and human breast cancer cell invasion Biol Chem 389 2008 447 453
53. V. Gocheva, and J.A. Joyce Cysteine cathepsins and the cutting edge of cancer invasion Cell Cycle 6 2007 60 64
54. V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, and et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis Genes Dev 20 2006 543 556
55. I. Gonzalez-Suarez, A.B. Redwood, D.A. Grotsky, M.A. Neumann, E.H. Cheng, C.L. Stewart, and et al. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair EMBO J 30 2011 3383 3396
56. L. Goretzki, M. Schmitt, K. Mann, J. Calvete, N. Chucholowski, M. Kramer, and et al. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L FEBS Lett 297 1992 112 118
57. T. Goto, T. Kiyoshima, R. Moroi, T. Tsukuba, Y. Nishimura, M. Himeno, and et al. Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy Histochemistry 101 1994 33 40
58. T. Goto, T. Tsukuba, T. Kiyoshima, Y. Nishimura, K. Kato, K. Yamamoto, and et al. Immunohistochemical localization of cathepsins B, D and L in the rat osteoclast Histochemistry 99 1993 411 414
59. M.M. Gottesman Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts Proc Natl Acad Sci U S A 75 1978 2767 2771
60. M.M. Gottesman, and M.E. Sobel Tumor promoters and Kirsten sarcoma virus increase synthesis of a secreted glycoprotein by regulating levels of translatable mRNA Cell 19 1980 449 455
61. B. Goulet, A. Baruch, N.S. Moon, M. Poirier, L.L. Sansregret, A. Erickson, and et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor Mol Cell 14 2004 207 219
62. B. Goulet, L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S.S. Chauhan, and et al. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation Mol Cancer Res 5 2007 899 907
63. B. Goulet, M. Truscott, and A. Nepveu A novel proteolytically processed CDP/Cux isoform of 90 kDa is generated by cathepsin L Biol Chem 387 2006 1285 1293
64. D.A. Grotsky, I. Gonzalez-Suarez, A. Novell, M.A. Neumann, S.C. Yaddanapudi, M. Croke, and et al. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells J Cell Biol 200 2013 187 202
65. G.P. Gupta, and J. Massague Cancer metastasis: building a framework Cell 127 2006 679 695
66. P. Hadji, M.S. Aapro, J.J. Body, N.J. Bundred, A. Brufsky, R.E. Coleman, and et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment Ann Oncol 22 2011 2546 2555
67. N. Harbeck, U. Alt, U. Berger, A. Kruger, C. Thomssen, F. Janicke, and et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy Clin Cancer Res 7 2001 2757 2764
68. L. Herszenyi, M. Plebani, P. Carraro, M. De Paoli, G. Roveroni, R. Cardin, and et al. The role of cysteine and serine proteases in colorectal carcinoma Cancer 86 1999 1135 1142
69. T. Hiwasa, and S. Sakiyama Nuclear localization of procathepsin L/MEP in ras-transformed mouse fibroblasts Cancer Lett 99 1996 87 91
70. C. Holroyd, C. Cooper, and E. Dennison Epidemiology of osteoporosis Best Pract Res Clin Endocrinol Metab 22 2008 671 685
71. X. Huang, A. Vaag, E. Carlsson, M. Hansson, B. Ahren, and L. Groop Impaired cathepsin L gene expression in skeletal muscle is associated with type 2 diabetes Diabetes 52 2003 2411 2418
72. K. Husmann, R. Muff, M.E. Bolander, G. Sarkar, W. Born, and B. Fuchs Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis Mol Carcinog 47 2008 66 73
73. S.R. Hwang, C. Garza, C. Mosier, T. Toneff, E. Wunderlich, P. Goldsmith, and et al. Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion J Biol Chem 282 2007 9556 9563
74. H. Inoue, K. Nishimura, D. Oka, Y. Nakai, M. Shiba, T. Tokizane, and et al. Prostate cancer mediates osteoclastogenesis through two different pathways Cancer Lett 223 2005 121 128
75. K. Ishidoh, and E. Kominami Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro Biochem Biophys Res Commun 217 1995 624 631
76. M. Jagodic, I. Vrhovec, S. Borstnar, and T. Cufer Prognostic and predictive value of cathepsins D and L in operable breast cancer patients Neoplasma 52 2005 1 9
77. M. Jain, S. Bakhshi, A.A. Shukla, and S.S. Chauhan Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers Ann Hematol 89 2010 1223 1232
78. D. Jean, M. Bar-Eli, S. Huang, K. Xie, F. Rodrigues-Lima, J. Hermann, and et al. A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma Cancer Res 56 1996 254 258
79. D. Jean, N. Guillaume, and R. Frade Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity Biochem J 361 2002 173 184
80. D. Jean, J. Hermann, F. Rodrigues-Lima, M. Barel, M. Balbo, and R. Frade Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L Biochem J 312 Pt 3 1995 961 969
81. D. Jean, N. Rousselet, and R. Frade Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms Oncogene 25 2006 1474 1484
82. A.B. Jensen, C. Wynne, G. Ramirez, W. He, Y. Song, Y. Berd, and et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial Clin Breast Cancer 10 2010 452 458
83. J.A. Joyce, A. Baruch, K. Chehade, N. Meyer-Morse, E. Giraudo, F.Y. Tsai, and et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Cancer Cell 5 2004 443 453
84. J.A. Joyce, and J.W. Pollard Microenvironmental regulation of metastasis Nat Rev Cancer 9 2009 239 252
85. T. Kageshita, A. Yoshii, T. Kimura, K. Maruo, T. Ono, M. Himeno, and et al. Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours Arch Dermatol Res 287 1995 266 272
86. H. Kakegawa, K. Tagami, Y. Ohba, K. Sumitani, T. Kawata, and N. Katunuma Secretion and processing mechanisms of procathepsin L in bone resorption FEBS Lett 370 1995 78 82
87. N. Katunuma Structure-based development of specific inhibitors for individual cathepsins and their medical applications Proc Jpn Acad Ser B Phys Biol Sci 87 2011 29 39
88. N. Katunuma, H. Tsuge, M. Nukatsuka, T. Asao, and M. Fukushima Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells Arch Biochem Biophys 397 2002 305 311
89. N. Katunuma, H. Tsuge, M. Nukatsuka, and M. Fukushima Structure-based development of cathepsin L inhibitors and therapeutic applications for prevention of cancer metastasis and cancer-induced osteoporosis Adv Enzyme Regul 42 2002 159 172
90. V. Kedinger, L. Sansregret, R. Harada, C. Vadnais, C. Cadieux, K. Fathers, and et al. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin J Biol Chem 284 2009 27701 27711
91. S. Keerthivasan, G. Keerthivasan, S. Mittal, and S.S. Chauhan Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells Gene 399 2007 129 136
92. E.T. Keller, and J. Brown Prostate cancer bone metastases promote both osteolytic and osteoblastic activity J Cell Biochem 91 2004 718 729
93. M.N. Khan, and A.A. Khan Cancer treatment-related bone loss: a review and synthesis of the literature Curr Oncol 15 2008 S30 S40
94. H. Kirschke, R. Eerola, V.K. Hopsu-Havu, D. Bromme, and E. Vuorio Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells Eur J Cancer 36 2000 787 795
95. H. Kirschke, A.A. Kembhavi, P. Bohley, and A.J. Barrett Action of rat liver cathepsin L on collagen and other substrates Biochem J 201 1982 367 372
96. G.D. Kishore Kumar, G.E. Chavarria, A.K. Charlton-Sevcik, W.M. Arispe, M.T. Macdonough, T.E. Strecker, and et al. Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors Bioorg Med Chem Lett 20 2010 1415 1419
97. S. Krueger, U. Kellner, F. Buehling, and A. Roessner Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype Cancer Gene Ther 8 2001 522 528
98. A. Kruger, R.E. Kates, and D.R. Edwards Avoiding spam in the proteolytic Internet: future strategies for anti-metastatic MMP inhibition Biochim Biophys Acta 1803 2010 95 102
99. G.D. Kumar, G.E. Chavarria, A.K. Charlton-Sevcik, G.K. Yoo, J. Song, T.E. Strecker, and et al. Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L Bioorg Med Chem Lett 20 2010 6610 6615
100. T.T. Lah, G. Calaf, E. Kalman, B.G. Shinde, R. Somers, S. Estrada, and et al. Cathepsins D, B, and L in transformed human breast epithelial cells Breast Cancer Res Treat 39 1996 221 233
101. T.T. Lah, M. Cercek, A. Blejec, J. Kos, E. Gorodetsky, R. Somers, and et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators Clin Cancer Res 6 2000 578 584
102. T.T. Lah, M.B. Duran Alonso, and C.J. Van Noorden Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6 2006 257 279
103. T.T. Lah, M. Hawley, K.L. Rock, and A.L. Goldberg Gamma-interferon causes a selective induction of the lysosomal proteases, cathepsins B and L, in macrophages FEBS Lett 363 1995 85 89
104. T.T. Lah, E. Kalman, D. Najjar, E. Gorodetsky, P. Brennan, R. Somers, and et al. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis Hum Pathol 31 2000 149 160
105. T.T. Lah, J. Kos, A. Blejec, S. Frkovic-Georgio, R. Golouh, I.I. Vrhovec, and et al. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease Pathol Oncol Res 3 1997 89 99
106. T.H. Lang, U. Willinger, and G. Holzer Soluble cathepsin-L: a marker of bone resorption and bone density? J Lab Clin Med 144 2004 163 166
107. J.M. Lankelma, D.M. Voorend, T. Barwari, J. Koetsveld, A.H. Van der Spek, A.P. De Porto, and et al. Cathepsin L, target in cancer treatment? Life Sci 86 2010 225 233
108. V. Laurent-Matha, D. Derocq, C. Prebois, N. Katunuma, and E. Liaudet-Coopman Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B J Biochem 139 2006 363 371
109. R. Lemaire, G. Huet, F. Zerimech, G. Grard, C. Fontaine, B. Duquesnoy, and et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells Br J Rheumatol 36 1997 735 743
110. G. Leto, M.V. Sepporta, M. Crescimanno, C. Flandina, and F.M. Tumminello Cathepsin L in metastatic bone disease: therapeutic implications Biol Chem 391 2010 655 664
111. G. Leto, F.M. Tumminello, G. Pizzolanti, G. Montalto, M. Soresi, A. Carroccio, and et al. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis Pancreas 14 1997 22 27
112. N. Levicar, R.A. Dewey, E. Daley, T.E. Bates, D. Davies, J. Kos, and et al. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis Cancer Gene Ther 10 2003 141 151
113. C. Lopez-Otin, and L.M. Matrisian Emerging roles of proteases in tumour suppression Nat Rev Cancer 7 2007 800 808
114. S.J. Lunt, N. Chaudary, and R.P. Hill The tumor microenvironment and metastatic disease Clin Exp Metastasis 26 2009 19 34
115. M. Macabeo-Ong, C.H. Shiboski, S. Silverman, D.G. Ginzinger, N. Dekker, D.T. Wong, and et al. Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression Oral Oncol 39 2003 638 647
116. R.A. Maciewicz, S.F. Wotton, D.J. Etherington, and V.C. Duance Susceptibility of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L FEBS Lett 269 1990 189 193
117. X. Mao, and R.A. Hamoudi Molecular and cytogenetic analysis of glioblastoma multiforme Cancer Genet Cytogenet 122 2000 87 92
118. R.W. Mason, S. Gal, and M.M. Gottesman The identification of the major excreted protein (MEP) from a transformed mouse fibroblast cell line as a catalytically active precursor form of cathepsin L Biochem J 248 1987 449 454
119. R.W. Mason, D.A. Johnson, A.J. Barrett, and H.A. Chapman Elastinolytic activity of human cathepsin L Biochem J 233 1986 925 927
120. S.D. Mason, and J.A. Joyce Proteolytic networks in cancer Trends Cell Biol 21 2011 228 237
121. B.A. Mincey, M.S. Duh, S.K. Thomas, E. Moyneur, M. Marynchencko, S.P. Boyce, and et al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors Clin Breast Cancer 7 2006 127 132
122. K. Miyamoto, M. Iwadate, Y. Yanagisawa, E. Ito, J. Imai, M. Yamamoto, and et al. Cathepsin L is highly expressed in gastrointestinal stromal tumors Int J Oncol 39 2011 1109 1115
123. M.M. Mohamed, and B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat Rev Cancer 6 2006 764 775
124. N.S. Moon, W. Rong Zeng, P. Premdas, M. Santaguida, G. Berube, and A. Nepveu Expression of N-terminally truncated isoforms of CDP/CUX is increased in human uterine leiomyomas Int J Cancer 100 2002 429 432
125. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
126. T. Nakase, M. Kaneko, T. Tomita, A. Myoui, K. Ariga, K. Sugamoto, and et al. Immunohistochemical detection of cathepsin D, K, and L in the process of endochondral ossification in the human Histochem Cell Biol 114 2000 21 27
127. T. Nakashima, R. Yasumatsu, M. Masuda, G.L. Clayman, and S. Komune Prognostic value of cathepsin L and its inhibitor headpin in oral squamous cell carcinoma J Laryngol Otol 126 2012 1134 1137
128. R. Navab, J.S. Mort, and P. Brodt Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64 Clin Exp Metastasis 15 1997 121 129
129. H.L. Neville-Webbe, and R.E. Coleman Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease Eur J Cancer 46 2010 1211 1222
130. M. Niedergethmann, B. Wostbrock, J.W. Sturm, F. Willeke, S. Post, and R. Hildenbrand Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma Pancreas 29 2004 204 211
131. M. Nilsen-Hamilton, R.T. Hamilton, W.R. Allen, and S.L. Massoglia Stimulation of the release of two glycoproteins from mouse 3T3 cells by growth factors and by agents that increase intralysosomal pH Biochem Biophys Res Commun 101 1981 411 417
132. Y. Nishida, K. Kohno, T. Kawamata, K. Morimitsu, M. Kuwano, and I. Miyakawa Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4 Gynecol Oncol 56 1995 357 361
133. M. Novinec, R.N. Grass, W.J. Stark, V. Turk, A. Baici, and B. Lenarcic Interaction between human cathepsins K, L, and S and elastins: mechanism of elastinolysis and inhibition by macromolecular inhibitors J Biol Chem 282 2007 7893 7902
134. T. Onishi, N. Hayashi, R.L. Theriault, G.N. Hortobagyi, and N.T. Ueno Future directions of bone-targeted therapy for metastatic breast cancer Nat Rev Clin Oncol 7 2010 641 651
135. C.M. Overall, and C. Lopez-Otin Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat Rev Cancer 2 2002 657 672
136. C. Palermo, and J.A. Joyce Cysteine cathepsin proteases as pharmacological targets in cancer Trends Pharmacol Sci 29 2008 22 28
137. I.C. Park, S.Y. Lee, D.G. Jeon, J.S. Lee, C.S. Hwang, B.G. Hwang, and et al. Enhanced expression of cathepsin L in metastatic bone tumors J Korean Med Sci 11 1996 144 148
138. M.G. Paulick, and M. Bogyo Application of activity-based probes to the study of enzymes involved in cancer progression Curr Opin Genet Dev 18 2008 97 106
139. I. Petermann, C. Mayer, J. Stypmann, M.L. Biniossek, D.J. Tobin, M.A. Engelen, and et al. Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice FASEB J 20 2006 1266 1268
140. J. Pfeilschifter, and I.J. Diel Osteoporosis due to cancer treatment: pathogenesis and management J Clin Oncol 18 2000 1570 1593
141. W. Potts, J. Bowyer, H. Jones, D. Tucker, A.J. Freemont, A. Millest, and et al. Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy Int J Exp Pathol 85 2004 85 96
142. E.M. Prence, J.M. Dong, and G.G. Sahagian Modulation of the transport of a lysosomal enzyme by PDGF J Cell Biol 110 1990 319 326
143. M.S. Rabin, P.J. Doherty, and M.M. Gottesman The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes Proc Natl Acad Sci U S A 83 1986 357 360
144. T.D. Rachner, P. Hadji, and L.C. Hofbauer Novel therapies in benign and malignant bone diseases Pharmacol Ther 134 2012 338 344
145. L.J. Raggatt, and N.C. Partridge Cellular and molecular mechanisms of bone remodeling J Biol Chem 285 2010 25103 25108
146. I.R. Reid Glucocorticoid osteoporosis - mechanisms and management Eur J Endocrinol 137 1997 209 217
147. I. Roato, P. D'Amelio, E. Gorassini, A. Grimaldi, L. Bonello, C. Fiori, and et al. Osteoclasts are active in bone forming metastases of prostate cancer patients PLoS One 3 2008 e3627
148. G.D. Roodman Mechanisms of bone metastasis N Engl J Med 350 2004 1655 1664
149. S. Roshy, B.F. Sloane, and K. Moin Pericellular cathepsin B and malignant progression Cancer Metastasis Rev 22 2003 271 286
150. J. Rozhin, R.L. Wade, K.V. Honn, and B.F. Sloane Membrane-associated cathepsin L: a role in metastasis of melanomas Biochem Biophys Res Commun 164 1989 556 561
151. A.M. Sadaghiani, S.H. Verhelst, V. Gocheva, K. Hill, E. Majerova, S. Stinson, and et al. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases Chem Biol 14 2007 499 511
152. Y. Saleh, M. Siewinski, W. Kielan, P. Ziolkowski, M. Grybos, and J. Rybka Regulation of cathepsin B and L expression in vitro in gastric cancer tissues by egg cystatin J Exp Ther Oncol 3 2003 319 324
153. M. Samaiya, S. Bakhshi, A.A. Shukla, L. Kumar, and S.S. Chauhan Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia J Cell Mol Med 15 2011 2189 2199
154. J. Schedel, C.A. Seemayer, T. Pap, M. Neidhart, S. Kuchen, B.A. Michel, and et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis Gene Ther 11 2004 1040 1047
155. C.D. Scher, R.L. Dick, A.P. Whipple, and K.L. Locatell Identification of a BALB/c-3T3 cell protein modulated by platelet-derived growth factor Mol Cell Biol 3 1983 70 81
156. G. Schwickert, S. Walenta, K. Sundfor, E.K. Rofstad, and W. Mueller-Klieser Correlation of high lactate levels in human cervical cancer with incidence of metastasis Cancer Res 55 1995 4757 4759
157. K. Sheahan, S. Shuja, and M.J. Murnane Cysteine protease activities and tumor development in human colorectal carcinoma Cancer Res 49 1989 3809 3814
158. R. Shridhar, J. Zhang, J. Song, B.A. Booth, C.G. Kevil, G. Sotiropoulou, and et al. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells Oncogene 23 2004 2206 2215
159. D.W. Siemann, and M.R. Horsman Modulation of the tumor vasculature and oxygenation to improve therapy Pharmacol Ther 153 2015 107 124
160. M. Siewinski, Y. Saleh, M. Gryboc, M. Murawski, G.B. Ekonjo, P. Ziolkowski, and et al. Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E J Exp Ther Oncol 4 2004 189 193
161. N. Singh, P. Das, S. Datta Gupta, P. Sahni, R.M. Pandey, S. Gupta, and et al. Prognostic significance of extracellular matrix degrading enzymes-cathepsin L and matrix metalloproteases-2 [MMP-2] in human pancreatic cancer Cancer Invest 31 2013 461 471
162. M. Sivaparvathi, M. Yamamoto, G.L. Nicolson, Z.L. Gokaslan, G.N. Fuller, L.A. Liotta, and et al. Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas Clin Exp Metastasis 14 1996 27 34
163. M. Skrzypczak, A. Springwald, C. Lattrich, J. Haring, S. Schuler, O. Ortmann, and et al. Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes Cancer Invest 30 2012 398 403
164. J.N. Snouwaert, L.C. Gowen, A.M. Latour, A.R. Mohn, A. Xiao, L. DiBiase, and et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene Oncogene 18 1999 7900 7907
165. E. Solau-Gervais, F. Zerimech, R. Lemaire, C. Fontaine, G. Huet, and R.M. Flipo Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis Scand J Rheumatol 36 2007 373 377
166. J. Song, L.M. Jones, G.E. Chavarria, A.K. Charlton-Sevcik, A. Jantz, A. Johansen, and et al. Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks Bioorg Med Chem Lett 23 2013 2801 2807
167. N.A. Stearns, J.M. Dong, J.X. Pan, D.A. Brenner, and G.G. Sahagian Comparison of cathepsin L synthesized by normal and transformed cells at the gene, message, protein, and oligosaccharide levels Arch Biochem Biophys 283 1990 447 457
168. J. Stypmann, K. Glaser, W. Roth, D.J. Tobin, I. Petermann, R. Matthias, and et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L Proc Natl Acad Sci U S A 99 2002 6234 6239
169. D.R. Sudhan, and D.W. Siemann Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells Clin Exp Metastasis 30 2013 891 902
170. S. Sulpizio, N. Franceschini, A. Piattelli, P. Di Sebastiano, P. Innocenti, and F. Selvaggi Cathepsins and pancreatic cancer: the 2012 update Pancreatology 12 2012 395 401
171. S. Sulpizio, N. Franceschini, A. Piattelli, P. Di Sebastiano, P. Innocenti, F. Cathepsins Selvaggi, and et al. Update Pancreatology 12 2012 395 401
172. R.S. Svatek, J. Karam, P.I. Karakiewicz, A. Gallina, R. Casella, C.G. Roehrborn, and et al. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma J Urol 179 2008 478 484 (discussion 484)
173. K. Tagami, H. Kakegawa, H. Kamioka, K. Sumitani, T. Kawata, B. Lenarcic, and et al. The mechanisms and regulation of procathepsin L secretion from osteoclasts in bone resorption FEBS Lett 342 1994 308 312
174. G.J. Tan, Z.K. Peng, J.P. Lu, and F.Q. Tang Cathepsins mediate tumor metastasis World J Biol Chem 4 2013 91 101
175. Q. Tang, J. Cai, D. Shen, Z. Bian, L. Yan, Y.X. Wang, and et al. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling J Mol Med (Berl) 87 2009 249 260
176. C. Thomssen, P. Oppelt, F. Janicke, K. Ulm, N. Harbeck, H. Hofler, and et al. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L Anticancer Res 18 1998 2173 2180
177. C. Thomssen, M. Schmitt, L. Goretzki, P. Oppelt, L. Pache, P. Dettmar, and et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer Clin Cancer Res 1 1995 741 746
178. K. Tomoo Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor Curr Top Med Chem 10 2010 696 707
179. A. Torkar, B. Lenarcic, T. Lah, V. Dive, and L. Devel Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors? Bioorg Med Chem Lett 23 2013 2968 2973
180. B.R. Troen, S. Gal, and M.M. Gottesman Sequence and expression of the cDNA for MEP (major excreted protein), a transformation-regulated secreted cathepsin Biochem J 246 1987 731 735
181. A.M. Troy, K. Sheahan, H.E. Mulcahy, M.J. Duffy, J.M. Hyland, and D.P. O'Donoghue Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression Eur J Cancer 40 2004 1610 1616
182. F.M. Tumminello, G. Leto, G. Pizzolanti, V. Candiloro, M. Crescimanno, L. Crosta, and et al. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression Anticancer Res 16 1996 2315 2319
183. B. Turk Targeting proteases: successes, failures and future prospects Nat Rev Drug Discov 5 2006 785 799
184. V. Turk, J. Brzin, M. Kotnik, B. Lenarcic, T. Popovic, A. Ritonja, and et al. Human cysteine proteinases and their protein inhibitors stefins, cystatins and kininogens Biomed Biochim Acta 45 1986 1375 1384
185. V. Turk, B. Turk, and D. Turk Lysosomal cysteine proteases: facts and opportunities EMBO J 20 2001 4629 4633
186. A. VanderWalde, and A. Hurria Aging and osteoporosis in breast and prostate cancer CA Cancer J Clin 61 2011 139 156
187. M. Verdoes, K. Oresic Bender, E. Segal, W.A. van der Linden, S. Syed, N.P. Withana, and et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity J Am Chem Soc 135 2013 14726 14730
188. S. Walenta, M. Wetterling, M. Lehrke, G. Schwickert, K. Sundfor, E.K. Rofstad, and et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers Cancer Res 60 2000 916 921
189. I.M. Ward, K. Minn, J. van Deursen, and J. Chen p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice Mol Cell Biol 23 2003 2556 2563
190. M. Watanabe, T. Higashi, M. Hashimoto, I. Tomoda, S. Tominaga, N. Hashimoto, and et al. Elevation of tissue cathepsin B and L activities in gastric cancer Hepatogastroenterology 34 1987 120 122
191. M. Watanabe, T. Higashi, A. Watanabe, T. Osawa, Y. Sato, Y. Kimura, and et al. Cathepsin B and L activities in gastric cancer tissue: correlation with histological findings Biochem Med Metab Biol 42 1989 21 29
192. E. Weber, D. Gunther, F. Laube, B. Wiederanders, and H. Kirschke Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth J Cancer Res Clin Oncol 120 1994 564 567
193. X. Xu, G. Yuan, W. Liu, Y. Zhang, and W. Chen Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance Exp Oncol 31 2009 102 105
194. T. Yamaguchi, K. Naruishi, H. Arai, F. Nishimura, and S. Takashiba IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts J Cell Physiol 217 2008 423 432
195. J.A. Yan, H. Xiao, H.X. Ji, W.H. Shen, Z.S. Zhou, B. Song, and et al. Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder J Int Med Res 38 2010 1913 1922
196. Z. Yang, and J.L. Cox Cathepsin L increases invasion and migration of B16 melanoma Cancer Cell Int 7 2007 8
197. S. Yasothornsrikul, D. Greenbaum, K.F. Medzihradszky, T. Toneff, R. Bundey, R. Miller, and et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter Proc Natl Acad Sci U S A 100 2003 9590 9595
198. I. Zajc, N. Sever, A. Bervar, and T.T. Lah Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines Cancer Lett 187 2002 185 190
199. J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E.T. Keller Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone Cancer Res 63 2003 7883 7890
200. W. Zhang, H.C. Yang, Q. Wang, Z.J. Yang, H. Chen, S.M. Wang, and et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis Anticancer Res 31 2011 3423 3428
201. X. Zheng, P.M. Chou, B.L. Mirkin, and A. Rebbaa Senescence-initiated reversal of drug resistance: specific role of cathepsin L Cancer Res 64 2004 1773 1780
202. X. Zheng, F. Chu, P.M. Chou, C. Gallati, U. Dier, B.L. Mirkin, and et al. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism Am J Physiol Cell Physiol 296 2009 C65 C74
203. S. Zucker, and J. Cao Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther 8 2009 2371 2373
204. S. Zucker, J. Cao, and W.T. Chen Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment Oncogene 19 2000 6642 6650